Alopecia em pacientes anticoagulados

Alopecia em pacientes anticoagulados

Resumo A alopecia é uma complicação comum da terapia anticoagulante que pode ter repercussões psicológicas importantes nos pacientes, especialmente nos do sexo feminino, e interferir na decisão de extensão da anticoagulação. Esta revisão tem como objetivo descrever os mecanismos potencialmente envol...

Full description

Bibliographic Details
Main Authors:	Marcos Arêas Marques, Carmen Lucia Lascasas Porto, Ana Letícia de Matos Milhomens, Juliana de Miranda Vieira, Claudia Carvalho Alcântara Gomes, Ana Thereza Cavalcanti Rocha, Cíntia da Silva Miller
Format:	Article
Language:	English
Published:	Sociedade Brasileira de Angiologia e de Cirurgia Vascular (SBACV)
Series:	Jornal Vascular Brasileiro
Subjects:	alopecia drug-related side effects and adverse reactions warfarin heparin anticoagulants rivaroxaban
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-54492020000100406&lng=en&tlng=en

Similar Items

Thromboembolic recurrence frequency analysis in patients with deep vein thrombosis of lower extremities.
by: Sergyi Vasyliuk, et al.
Published: (2020-03-01)

Análise do grau de recanalização da trombose venosa profunda: estudo comparativo de pacientes tratados com varfarina versus rivaroxabana
by: Polyana Klomfass Piati, et al.

ПРИМЕНЕНИЕ ПЕРОРАЛЬНЫХ АНТИКОАГУЛЯНТОВ ПРИ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ: СОВРЕМЕННОЕ СОСТОЯНИЕ ПРОБЛЕМЫ И НОВЫЕ ВОЗМОЖНОСТИ
by: Г. И. Сторожаков, et al.
Published: (2013-04-01)

Rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism in African American patients: a retrospective cohort analysis
by: Olivia S. Costa, et al.
Published: (2020-04-01)

Updates in Anticoagulation Therapy Monitoring
by: Hannah L. McRae, et al.
Published: (2021-03-01)

Approaches for the prevention and treatment of venous thromboembolism in a patient with anaplastic astrocytoma: a case report
by: M. G. Pavlova, et al.
Published: (2021-09-01)

Old and New anticoagulants: The beginning of a new era?
by: Fidel Cáceres Loriga, et al.
Published: (2011-01-01)

Analysis of Anticoagulant Therapy in the Elderly Patients, in Clinical Practice of Family Medicine Centers in the Kyrgyz Republic
by: S. M. Mamatov, et al.
Published: (2021-05-01)

Prevention of heart embolic complications in atrial fibrillation: Possibilities of using rivaroxaban
by: I S Iavelov
Published: (2013-12-01)

The Anticoagulated trauma patient in the age of the direct oral anticoagulants: a Canadian perspective
by: Brendan Wood, et al.
Published: (2017-08-01)

Atrial fibrillation and stroke in the perspective of new oral anticoagulants
by: Demet Funda Baş, et al.
Published: (2013-02-01)

Prescribing of direct oral anticoagulants and warfarin to older people with atrial fibrillation in UK general practice: a cohort study
by: Anneka Mitchell, et al.
Published: (2021-08-01)

Control Of Anticoagulation Therapy in Atrial Fibrillation (COAT-AF Study) in Real Clinical Practice
by: A. A. Zarudsky, et al.
Published: (2020-03-01)

Anticoagulated patients exhibit intact endogenous thrombin potential using ST Genesia unlike the Calibrated Automated Thrombogram
by: Tuukka A. Helin, et al.
Published: (2021-03-01)

Oral anticoagulants in the prevention of thromboembolic complications in cardiac patients: analysis of use in the Russian Federation
by: A. A. Gruzdeva, et al.
Published: (2020-05-01)

NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY
by: D. A. Napalkov, et al.
Published: (2015-09-01)

Gastrointestinal Bleeding and Direct Oral Anticoagulants among Patients with Atrial Fibrillation: Risk, Prevention, Management, and Quality of Life
by: Paolo Zappulla, et al.
Published: (2021-04-01)

Anti-Coagulation During Pregnancy in Women with Mechanical Heart Valves: A Prospective Study
by: Amir Jamshid Khamoushi, et al.
Published: (2011-04-01)

Clinical impact of a pharmacist-led inpatient anticoagulation service: a review of the literature
by: Lee T, et al.
Published: (2016-05-01)

Fatal consequences of synergistic anticoagulation
by: Sen P, et al.
Published: (2018-05-01)

Osteoporosis and antithrombotic therapy
by: N. V. Brailova, et al.
Published: (2021-06-01)

Efficacy and Safety of Oral Anticoagulants in Patients with Systolic Heart Failure in Sinus Rhythm: A Systematic Review and Meta-analysis of Randomized Controlled Trials and Cohort Studies
by: Marie H. Nygaard, et al.
Published: (2020-10-01)

Direct oral anticoagulants and warfarin for venous thromboembolism treatment: Trends from 2012 to 2017
by: Pamela L. Lutsey, et al.
Published: (2019-10-01)

Quantitative Systems Pharmacology Model-Based Predictions of Clinical Endpoints to Optimize Warfarin and Rivaroxaban Anti-Thrombosis Therapy
by: Sonja Hartmann, et al.
Published: (2020-07-01)

Perioperative venous thromboembolic disease and the emerging role of the novel oral anticoagulants: An analysis of the implications for perioperative management
by: Martina Mookadam, et al.
Published: (2015-01-01)

Safety of ECT in patients receiving an oral anticoagulant
by: Centanni, N.R, et al.
Published: (2021)

ANTICOAGULANT THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: DRUG CHOICE AND DOSAGE ADJUSTMENT
by: E. L. Dolgova, et al.
Published: (2015-09-01)

Changes in prescribing antithrombotic therapy in patients with atrial fibrillation and myocardial infarction in 2016-2019
by: K. G. Pereverzeva, et al.
Published: (2020-08-01)

Anticoagulants and Osteoporosis
by: Salvatore Santo Signorelli, et al.
Published: (2019-10-01)

Anticoagulation for Radiation-Induced Optic Neuropathy
by: Narayanaswamy Venketasubramanian, et al.
Published: (2020-12-01)

The Anticoagulation in Patients with Atrial Fibrillation: Rivaroxaban and Warfarin
by: I. Yu. Koroleva, et al.
Published: (2016-11-01)

PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN ATRIAL FIBRILLATION - RAT POISON OR NEW ORAL ANTICOAGULANTS: DO WE HAVE A CHOICE, AND SHOULD WE BE AFRAID TO MAKE IT? FIRST CLINICAL EXPERIENCE WITH RIVAROXABAN IN NIZHNY NOVGOROD
by: L. Y. Koroleva, et al.
Published: (2015-12-01)

PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN ATRIAL FIBRILLATION - RAT POISON OR NEW ORAL ANTICOAGULANTS: DO WE HAVE A CHOICE, AND SHOULD WE BE AFRAID TO MAKE IT? FIRST CLINICAL EXPERIENCE WITH RIVAROXABAN IN NIZHNY NOVGOROD
by: L. Y. Koroleva, et al.
Published: (2015-09-01)

Direct Oral Anticoagulants as Successful Treatment of Heparin-Induced Thrombocytopenia: A Parisian Retrospective Case Series
by: Julie Carré, et al.
Published: (2021-08-01)

Rivaroxaban versus warfarin for the management of left ventricle thrombus
by: Monirah A. Albabtain, et al.
Published: (2021-05-01)

Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulants
by: Turagam MK, et al.
Published: (2015-09-01)

Continuous warfarin administration versus heparin bridging therapy in post colorectal polypectomy haemorrhage: a study protocol for a multicentre randomised controlled trial (WHICH study)
by: Yasuaki Nagami, et al.
Published: (2021-01-01)

Fondaparinux Outpatient Use for Patients with a Heparin-Induced Thrombocytopenia History: A Case Report and Review
by: Amy Christopher
Published: (2016-12-01)

Current approaches to periprocedural anticoagulation treatment in patients undergoing atrial fibrillation ablation
by: N. Z. Gasymova, et al.
Published: (2019-05-01)

Rivaroxaban – a safe therapeutic option in patients with antiphospholipid syndrome? Our experience in 23 cases
by: Ewa Haładyj, et al.
Published: (2016-07-01)

Cannot write session to /tmp/vufind_sessions/sess_e9fh8422mq61b58slo692bheo7